ConductScience.org, home

Paper36280752

Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.

Wolf G and 7 others. Mol Psychiatry, 2023. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Papers, record 36280752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36280752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.
PubMed
Journal
Mol Psychiatry
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
3.37
iCite
Revised in PubMed
2026-10-30
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolf GGilly
2Singh SSandeep
3Blakolmer KKarin
4Lerer LLeonard
5Lifschytz TTzuri
6Heresco-Levy UUriel
7Lotan AAmithttps://orcid.org/0000-0001-7628-0975
8Lerer BBernardhttps://orcid.org/0000-0002-9914-632X

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HallucinogensMajor topic
SchizophreniaMajor topic
Psychotic DisordersMajor topic
Antipsychotic AgentsMajor topic
Animals
Humans

References212

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131664453Schizophrenia-An Overview.JAMA Psychiatry2020https://conductscience.org/library/papers/31664453PubMed
230262987Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics.J Exp Neurosci2018https://conductscience.org/library/papers/30262987PubMed
323609382Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.J Clin Psychopharmacol2013https://conductscience.org/library/papers/23609382PubMed
429898390Psychedelics Promote Structural and Functional Neural Plasticity.Cell Rep2018https://conductscience.org/library/papers/29898390PubMed
58251869Adverse consequences of lysergic acid diethylamide.Addiction1993https://conductscience.org/library/papers/8251869PubMed
616269092Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.J Cogn Neurosci2005https://conductscience.org/library/papers/16269092PubMed
722561603Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry2012https://conductscience.org/library/papers/22561603PubMed
816172203Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med2005https://conductscience.org/library/papers/16172203PubMed
917015232Neurobiology of schizophrenia.Neuron2006https://conductscience.org/library/papers/17015232PubMed
1032110026Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment.Neuropsychiatr Dis Treat2020https://conductscience.org/library/papers/32110026PubMed
1131065731MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.Psychopharmacology (Berl)2019https://conductscience.org/library/papers/31065731PubMed
1232042038Emotions and brain function are altered up to one month after a single high dose of psilocybin.Sci Rep2020https://conductscience.org/library/papers/32042038PubMed
1320618446Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia.Genes Brain Behav2010https://conductscience.org/library/papers/20618446PubMed
1425392249Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation.J Dual Diagn2014https://conductscience.org/library/papers/25392249PubMed
1517349858Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.Int Rev Neurobiol2007https://conductscience.org/library/papers/17349858PubMed
1633328244Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.Pharmacol Rev2021https://conductscience.org/library/papers/33328244PubMed
1731568558Acute effects of lysergic acid diethylamide (LSD) on resting brain function.Swiss Med Wkly2019https://conductscience.org/library/papers/31568558PubMed
1825744618Psychedelics not linked to mental health problems or suicidal behavior: a population study.J Psychopharmacol2015https://conductscience.org/library/papers/25744618PubMed
1933252694Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.Int J Neuropsychopharmacol2021https://conductscience.org/library/papers/33252694PubMed
201149803Behavioral effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rats and mice.Eur J Pharmacol1975https://conductscience.org/library/papers/1149803PubMed

See all 212 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42471435Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology2026https://conductscience.org/library/papers/42471435PubMed
42345450The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.J Psychopharmacol2026https://conductscience.org/library/papers/42345450PubMed
42154264Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis.Eur Arch Psychiatry Clin Neurosci2026https://conductscience.org/library/papers/42154264PubMed
41446307How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.Front Psychiatry2025https://conductscience.org/library/papers/41446307PubMed
40530408Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.Psychedelic Med (New Rochelle)2025https://conductscience.org/library/papers/40530408PubMed
40514369Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration.Transl Psychiatry2025https://conductscience.org/library/papers/40514369PubMed
40162511Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.Psychol Med2025https://conductscience.org/library/papers/40162511PubMed
39592825Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Mol Psychiatry2025https://conductscience.org/library/papers/39592825PubMed
39446321Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis.JAMA Netw Open2024https://conductscience.org/library/papers/39446321PubMed
39260466A Computational Account of the Development and Evolution of Psychotic Symptoms.Biol Psychiatry2025https://conductscience.org/library/papers/39260466PubMed
38923845Psychotomimetic compensation versus sensitization.Pharmacol Res Perspect2024https://conductscience.org/library/papers/38923845PubMed
38919636Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.Front Psychiatry2024https://conductscience.org/library/papers/38919636PubMed
38491857Psychiatric risks for worsened mental health after psychedelic use.J Psychopharmacol2024https://conductscience.org/library/papers/38491857PubMed
38280572Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.J Affect Disord2024https://conductscience.org/library/papers/38280572PubMed
37945694Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.Mol Psychiatry2024https://conductscience.org/library/papers/37945694PubMed
37935376Ligand recognition and G-protein coupling of trace amine receptor TAAR1.Nature2023https://conductscience.org/library/papers/37935376PubMed
37899392Psychedelics action and schizophrenia.Pharmacol Rep2023https://conductscience.org/library/papers/37899392PubMed
37759040Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics.Mol Psychiatry2023https://conductscience.org/library/papers/37759040PubMed
37358825Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia.Schizophr Bull2023https://conductscience.org/library/papers/37358825PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
HTR2A3356PubTator's text mininghttps://conductscience.org/library/genes/3356

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36280752

GET https://conductscience.org/api/papers/v1/36280752/references?page=2